Gathering Provides Opportunity to Discuss Progress of CTD's International Clinical Program
ALACHUA, FL -- (Marketwired) -- 09/03/15 -- September 3, 2015 - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, will make a formal presentation on progress in its clinical trials program on September 19 at a major annual meeting of caregivers and families struggling with Niemann-Pick Type C (NPC) disease. The meeting will be convened in Bedfordshire, England, under the auspices of the Niemann-Pick UK, a registered charity in the United Kingdom. The annual meeting brings together experts from around the world for interactive sessions on clinical and practical management of NPC, and on clinical trials aimed at slowing the progression of the disease. The company's formal presentation will be held on Saturday, September 19.
"We look forward to sharing information on our company's history in meeting the needs of NPC families globally with Trappsol® Cyclo™, and having opportunities to interact directly with those most impacted by NPC," said Executive Chairman N. Scott Fine.
"We welcome discussions with families and health professionals about our international clinical program progress, and we are eager to work with NP-UK in hosting our Family and Physician Listening Circle," added Dr. Sharon Hrynkow, Scientific Advisory Board member and Senior Medical Advisor to the company.
On Friday, September 18, CTD Holdings will convene its Family and Physicians Listening Circle under the leadership of Co-Chair Sue French, an advocate for research into NPC cures and treatments. Listening Circle Member Dr. Robin Lachmann, a UK-based physician, will also participate. The Listening Circle is open to all families and caregivers in attendance at the conference. Its goal is to provide a platform for learning and sharing among families, caregivers, CTD Holdings and external scientific experts.
At the September 18 Listening Circle, Professor Frances Platt of the University of Oxford, a leading lysosomal storage disease expert, will discuss where cyclodextrin fits in the proposed treatment options for NPC and some of the unanswered questions about how it mediates its benefit in this disease.
About the Company:
CTD Holdings, Inc. is a biotechnology company developing cyclodextrin-based products for the treatment of disease, including Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann-Pick Type C, a rare and often fatal genetic disease in young children which also results in significant health impairment for affected adults. Additional indications for the active ingredient in Trappsol® Cyclo™, including peripheral artery disease, diabetic nephropathy, and acute viral infections, are also in development.
The company's other divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in the research, pharmaceutical, medical device, cosmetics and nutrition markets. They also operate the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes and supply cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. For additional information, visit the company's websites: www.ctd-holdings.com and www.cyclodex.com
Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Source: CTD Holdings, Inc.
Source: CTD Holdings, Inc.